Tesamorelin 5 mg
ALL PRODUCTS

Tesamorelin 5 mg

Product Information

Compound Details

Dragon Pharma
Active Substance Tesamorelin Lyophilized GHRH analogue (GHRH 1-44)
5 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life Approximately 30–40 Minutes
Detection Up to several weeks
Primary Mechanism GHRH Receptor Agonism
GH / IGF-1 Impact Moderate to High
$42.00 $70.00
Shipping :
International
U.S. Domestic
You will save $28.00
Product Overview

Dragon Pharma Tesamorelin 5 mg — GHRH Analogue

Dragon Pharma Tesamorelin 5 mg supplies a lyophilized formulation of Tesamorelin, a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates endogenous growth hormone (GH) production and increases insulin-like growth factor-1 (IGF-1) levels. Unlike exogenous HGH, tesamorelin acts upstream at the pituitary, prompting the body's own GH release in a pulsatile pattern.

This Dragon Pharma formulation provides 5 mg of Tesamorelin per 2 mL vial in lyophilized powder form, requiring reconstitution before laboratory use. Tesamorelin is approved by the FDA as EGRIFTA/EGRIFTA SV for a specific indication: reducing excess abdominal fat in HIV-infected patients with lipodystrophy. It is not approved for weight loss, bodybuilding, or general use, and the label explicitly states it is not indicated for weight loss management. The approved product is a 2 mg daily subcutaneous injection with a short half-life of approximately 18–38 minutes.

Key Research Characteristics

  • GHRH Receptor Agonism: Binds pituitary GHRH receptors, stimulating GH synthesis and release, which in turn raises IGF-1 levels.
  • Visceral Fat Reduction: Meta-analysis of RCTs in HIV lipodystrophy showed significant reduction in visceral adipose tissue (−27.71 cm²) and trunk fat (−1.18 kg) versus placebo.
  • Lean Mass Increase: The same meta-analysis reported a significant increase in lean body mass (+1.42 kg).
  • Short Half-Life: Approximately 18.6 minutes after single dose and 37.8 minutes after multiple doses; requires daily subcutaneous injection.
  • IGF-1 Elevation: 47% of patients had IGF-1 levels >2 SDS after 26 weeks; 36% had >3 SDS.
  • Cancer Risk Warning: The label warns of increased risk of new cancer or cancer reactivation in HIV-positive patients.

How Tesamorelin Works

Tesamorelin is a 44-amino-acid GHRH analogue with a trans-3-hexenoyl modification that extends its stability against DPP-IV degradation. It binds GHRH receptors on somatotroph cells in the anterior pituitary, stimulating GH release. The resulting GH pulse then drives hepatic IGF-1 production, which mediates many of the anabolic and metabolic effects.

In the approved indication, this GH/IGF-1 axis stimulation reduces visceral adipose tissue without the systemic GH exposure of exogenous HGH. However, the label warns that prolonged IGF-1 elevation has unknown effects and requires monitoring. The clinical data is exclusively from HIV-infected patients with lipodystrophy; no trials have evaluated tesamorelin in healthy individuals for body composition or performance.

Tesamorelin vs. Other GH-Axis Peptides

Tesamorelin differs from growth hormone secretagogues like Ipamorelin 5 mg and CJC-1295 DAC 5 mg, which act on the ghrelin receptor to stimulate GH release. It is also distinct from Tesamorelin 5 mg in the Ipamorelin/Tesamorelin blend product, which combines two different mechanisms. Exogenous HGH (Dragontropin HGH 200 IU) bypasses the pituitary entirely, while tesamorelin depends on pituitary responsiveness.

Important Considerations

This product is a lyophilized research peptide supplied for laboratory investigation only. It is not the FDA-approved EGRIFTA product and is not intended for human consumption. Tesamorelin carries warnings for increased cancer risk, IGF-1 elevation, fluid retention, glucose intolerance, and hypersensitivity reactions. The approved drug is contraindicated in patients with active cancer, pituitary disorders, or pregnancy.

Formulation & Research Profile

Product Specifications

Labeled product attributes and general research reference data for Tesamorelin 5 mg.

Product & Formulation

Product NameTesamorelin 5 mg
Active IngredientTesamorelin (GHRH analogue; 44 amino acids)
Peptide ClassGrowth hormone-releasing hormone (GHRH) receptor agonist
Labeled Strength5 mg per vial
Dosage FormLyophilized powder
Package Contents2 mL vial containing 5 mg Tesamorelin
ManufacturerDragon Pharma
Administration RouteNot established for this research format; approved drug is subcutaneous injection

Pharmacological Profile

Primary MechanismGHRH receptor agonist; stimulates pituitary GH release and hepatic IGF-1 production
Molecular WeightApproximately 5,135 Da
Elimination Half-Life~18.6 min (single dose) to ~37.8 min (multiple doses)
TmaxApproximately 10 minutes post subcutaneous injection
IGF-1 Effect47% of patients >2 SDS, 36% >3 SDS after 26 weeks
Primary Clinical IndicationReduction of excess abdominal fat in HIV-infected patients with lipodystrophy
Regulatory StatusFDA-approved as EGRIFTA/EGRIFTA SV; not approved for weight loss or general use
Key WarningsCancer risk, IGF-1 elevation, fluid retention, glucose intolerance

Scientific References

Supporting research resources for the pharmacological information above.

Pharmacological values are general reference information. This product is supplied for laboratory research only. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy, not for weight loss or performance enhancement.

Laboratory Handling Context

Research Handling Information

Tesamorelin is supplied as lyophilized powder for laboratory research. The FDA-approved product has a specific daily subcutaneous dosing schedule for HIV lipodystrophy; this research vial is a different format with no established human protocol.

Reconstitution Overview

Lyophilized Tesamorelin requires reconstitution with a suitable solvent before laboratory use. Bacteriostatic Water is commonly used for peptide reconstitution. For a 5 mg vial, adding 2 mL of solvent yields a concentration of 2.5 mg/mL. Gentle swirling—not vigorous shaking—is recommended to avoid peptide aggregation.

The approved EGRIFTA SV product is supplied as a 2 mg/vial formulation for daily subcutaneous injection into the abdomen. The label specifies rotating injection sites and not injecting into scar tissue, bruises, or the navel. The 5 mg research vial contains more than the daily clinical dose and is not a pharmaceutical equivalent. No pharmacokinetic data exists for this reconstituted research format.

Practical Handling Considerations

  • Reconstitution volume: 2 mL solvent yields 2.5 mg/mL; adjust volume to achieve the desired working concentration.
  • Solvent selection: Bacteriostatic water is standard for most peptide research.
  • Handling technique: Swirl gently; avoid vortexing or vigorous shaking.
  • Storage after reconstitution: Refrigerate reconstituted peptide; stability data for this specific product is not available. The approved product must be used immediately after mixing and should not be stored, frozen, or refrigerated after mixing.
  • Approved drug context: EGRIFTA SV uses 2 mg daily SC in the abdomen for HIV lipodystrophy; this is not a recommendation for research vials.
  • Related GH-axis peptides: Ipamorelin 5 mg acts on the ghrelin receptor; Sermorelin 5 mg is another GHRH analogue with a shorter half-life.

Important Research Notice

Tesamorelin has no established dosing protocol for reconstituted research vials. The FDA-approved product is indicated only for HIV-associated lipodystrophy and carries warnings for cancer risk, IGF-1 elevation, fluid retention, and glucose intolerance. This product is supplied strictly for laboratory research and is not intended for human administration.

Delivery & Fulfillment

Shipping & Delivery Information

Shipping estimates and fulfillment options vary by warehouse and product availability. Review the information below before placing your order.

Shipping Options & Delivery Estimates

International Warehouse

International Fulfillment
13–15 Business Days

Orders dispatched from our international warehouse typically arrive within 13–15 business days after dispatch. Delivery times may vary depending on destination, customs processing, and carrier conditions.

U.S. Domestic Warehouse

Domestic Fulfillment
4–5 Business Days

Eligible orders dispatched from our U.S. domestic warehouse typically arrive within 4–5 business days after dispatch. This option is available only for products stocked in the domestic warehouse.

Important Shipping Information

  • Warehouse availability: Not all products are available from both warehouses. Available shipping options are displayed on the product page.
  • Order processing: Delivery estimates begin when an order is dispatched, not when payment is completed. Processing time before dispatch is additional.
  • Shipment tracking: Tracking information is provided when available, according to the applicable shipping policy.
  • Delivery delays: Customs inspections, carrier disruptions, holidays, and other circumstances may affect estimated delivery times.

Full Shipping Policy

Review the complete shipping terms, delivery conditions, and applicable order policies before placing an order.

Shipping Policy
Product Care & Handling

Storage & Handling Guidelines

Lyophilized peptides require specific storage conditions to maintain stability. Follow the guidance below for Dragon Pharma Tesamorelin 5 mg.

Recommended Storage Conditions

Storage Temperature

Store lyophilized powder refrigerated at 2°C to 8°C or frozen at -20°C for long-term storage. Avoid repeated temperature fluctuations.

Moisture Protection

Keep the vial sealed and protected from humidity. Lyophilized peptides are hygroscopic; moisture exposure can degrade the peptide before reconstitution.

Light Exposure

Store in the original packaging or a dark container. The approved product should be kept out of the light.

Original Vial

Keep the lyophilized powder in the supplied vial until reconstitution. Allow refrigerated vials to reach room temperature before opening to prevent condensation.

Handling & Stability

  • Expiration date: Refer to the date printed on the vial, if present. No manufacturer-verified shelf life was supplied for this batch.
  • Shelf life (lyophilized): Generally stable for extended periods when refrigerated or frozen and protected from moisture; follow any manufacturer-printed date.
  • After reconstitution: Refrigerate and use within the timeframe specified by your laboratory protocol. The approved product must be used immediately after mixing and should not be stored.
  • Handling technique: Use sterile technique when reconstituting. Avoid repeated freeze-thaw cycles of reconstituted solution.
  • Child safety: Store in a locked refrigerator or cabinet inaccessible to children and pets.
  • Disposal: Dispose of unused peptide according to institutional or local laboratory waste guidelines.
Product Questions & Answers

Frequently Asked Questions

Common questions about Tesamorelin 5 mg, its research background, and laboratory handling.

01

What does peptide Tesamorelin do?

Tesamorelin is a GHRH analogue that stimulates pituitary growth hormone release, which in turn raises IGF-1 levels. It is FDA-approved specifically for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. Clinical trials in that population showed significant visceral fat reduction and lean mass increase. It is not approved for weight loss in general, and the label explicitly states it is not indicated for weight loss management.

02

What not to mix with Tesamorelin?

The FDA label does not list specific drug-drug interactions for tesamorelin, but it warns of additive effects with other GH-acting agents and advises telling your doctor about all medicines. The approved product is contraindicated in patients with active cancer, pituitary disorders, or pregnancy. It should not be mixed with other peptides in the same syringe unless compatibility has been established—no such data exists for this research peptide.

03

Is it okay to take Tesamorelin every day?

The FDA-approved EGRIFTA product is dosed as a once-daily subcutaneous injection. Its half-life is short (~18–38 minutes), so daily dosing is required for sustained effect. However, this schedule applies to the approved pharmaceutical formulation under medical supervision, not to reconstituted research vials. Self-administration of research-grade tesamorelin has no established safety or dosing data.

04

Is this the same as EGRIFTA?

No. EGRIFTA/EGRIFTA SV is the FDA-approved prescription product with a specific formulation (2 mg/vial) and indication (HIV lipodystrophy). This Dragon Pharma product is a 5 mg lyophilized research peptide requiring reconstitution. They are not interchangeable, and the research vial has no established human dosing or safety profile.

05

What are the side effects of Tesamorelin?

The approved label lists arthralgia, myalgia, paresthesia, injection-site reactions, fluid retention, and glucose intolerance as common adverse effects. More serious warnings include increased risk of new cancer or cancer reactivation, elevated IGF-1 levels, and hypersensitivity reactions. In clinical trials, 25% of tesamorelin-treated patients experienced injection-site reactions versus 14% on placebo.

06

Does Tesamorelin increase muscle mass?

In HIV lipodystrophy trials, tesamorelin increased lean body mass by 1.42 kg compared to placebo. A separate analysis showed increased lean muscle area in four muscle groups, with effects largely explained by IGF-1 elevation. These findings are specific to a disease population with lipodystrophy; no trials have evaluated tesamorelin for muscle growth in healthy bodybuilders.

07

How should I store lyophilized Tesamorelin?

Store the lyophilized powder refrigerated (2–8°C) or frozen (-20°C), protected from light and moisture. Allow vials to reach room temperature before opening to prevent condensation. After reconstitution, use according to your laboratory protocol. The approved product must be used immediately after mixing and should not be stored. Avoid repeated freeze-thaw cycles.

08

Is Tesamorelin FDA-approved for weight loss?

No. The FDA label explicitly states "EGRIFTA is not indicated for weight loss management". Its only approved indication is reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Using it for general weight loss or bodybuilding is outside the approved indication and carries the label's warnings for cancer risk, IGF-1 elevation, and metabolic effects.

No reviews yet.

Have you tried this product? Share your experience to help other customers. Log in to write a review.

Related Products
Domestic & International
Bacteriostatic Water
Dragon Pharma, Europe
Product Information

Compound Details

Dragon Pharma
Active Substance Bacteriostatic Water Sterile water with 0.9% benzyl alcohol (diluent)
0.9% benzyl alcohol
Form Liquid Solution
Packaging 10 mL Vial
Preservative 0.9% Benzyl Alcohol
$20.00
Laboratory Tested
Domestic & International
You will save $16.00
-40% OFF
BPC 157 5 mg
Dragon Pharma, Europe
Product Information

Compound Details

Dragon Pharma
Active Substance BPC-157 Lyophilized synthetic pentadecapeptide
5 mg per vial
Form Lyophilized Powder
Packaging 2 mL Multidose Vial
Estimated Half-Life Limited human data
Detection Up to several weeks
Primary Mechanism Angiogenesis / VEGF Pathway Upregulation
Tissue Repair / Healing High (preclinical)
Latest Laboratory Result 4.99 mg Mar 22, 2024 · Batch HD23BC View Report
$24.00 $40.00
You will save $16.00
Laboratory Tested
Shipped International
You will save $32.00
-40% OFF
TB 500 5 mg/BPC 157 5 mg
Dragon Pharma, Europe
Product Information

Compound Details

Dragon Pharma
Active Formula 2 Actives
Thymosin Beta-4 5 mg
BPC-157 5 mg
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life Short-acting
Detection Up to several weeks
Primary Mechanism Actin Regulation + Angiogenesis (Dual Pathway)
Tissue Repair / Healing High
Latest Laboratory Result 5.43 mg · 4.95 mg Apr 26, 2024 · Batch BTHD24 View Report
$48.00 $80.00
You will save $32.00

Add to Cart - Product(s)

Close Button
Empty

Total Cost: